Clinical Trial: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational



Official Title: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL), Lmphoplasmacytic Lymphoma(LPL)/Waldenstro

Brief Summary:

Background:

The development of new technologies now allow scientists to investigate the molecular basis and clinical manifestations of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). Applying these methods in a natural history study can clarify processes involved in disease progression and possibly lead to the discovery or validation of treatment targets.

  • Objectives:

    • Study the biology and natural history of MBL/CLL/SLL in patients prior to the time when their disease requires treatment and the biology of LPL/WM and SMZL.
    • Characterize clinical, biologic and molecular events of disease stability and progression of patients enrolled on this protocol.

  • Eligibility:

    • Diagnosis of MBL/CLL/SLL/LPL/WM/SMZL
    • Age greater than or equal to 18 years.
    • Patients with CLL/SLL must not have received previous cytotoxic, monoclonal antibody, or kinase inhibitor therapy.
    • Patients with LPL/WM or SMZL can have prior therapy.
    • ECOG performance status of 0-2.

  • Design: